AdvanCell is a radiopharmaceutical company that is developing a revolutionary cancer treatment called Targeted Alpha Therapy, providing new hope for patients with untreatable cancers.
News
AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026
AdvanCell to Present Updated Phase 1b Results from the TheraPb Trial at ESMO Congress 2026
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure
AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy
AdvanCell Establishes U.S. Global Headquarters and Secures Flagship Manufacturing Facility in Greater Boston to Drive Growth Strategy
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
Dr. Oliver Sartor interviews AdvanCell CMO Dr. Anna Karmann on TheraPb Phase 2 for UroToday
Presentation of the Novel Study Design for the Phase 2 Expansion Study of 212Pb-ADVC001 in Metastatic Prostate Cancer: The TheraPb Trial
Presentation of the Novel Study Design for the Phase 2 Expansion Study of 212Pb-ADVC001 in Metastatic Prostate Cancer: The TheraPb Trial
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medical Need
AdvanCell Announces Upcoming Presentation of TheraPb Phase 2 Expansion Study Design at ASCO Genitourinary Cancers Symposium 2026
AdvanCell Announces Upcoming Presentation of TheraPb Phase 2 Expansion Study Design at ASCO Genitourinary Cancers Symposium 2026
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth
TheraPb Phase 1b results featured by Urology Times in an interview with Principal investigator Aaron Hansen
TheraPb Phase 1b results featured by Urology Times in an interview with Principal investigator Aaron Hansen
AdvanCell featured as Emerging Company by BioCentury
AdvanCell featured as Emerging Company by BioCentury
AdvanCell to participate in Jefferies Global Healthcare Conference in London
AdvanCell to participate in Jefferies Global Healthcare Conference in London
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
Results from the Phase 1b dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer: The TheraPb trial
Results from the Phase 1b dose escalation of 212Pb-ADVC001 in PSMA-positive metastatic castration-resistant prostate cancer: The TheraPb trial
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
Alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
Alpha-Therapy and Combination Strategies to Overcome Resistance and Enhance Clinical Outcomes in Prostate Cancer
AdvanCell to Highlight the Potential of Pb-212-based Targeted Alpha Therapies for Cancer at EANM’25
